Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma

Journal of Cellular Physiology

Volumn 200, Issue 2, 2004, Pages 272-276

  Altomonte, Maresa ^a   Visintin, Alberto ^a   Tecce, Raffaele ^b   Leonardi, Antonio ^c   Calabro, Luana ^a   Fonsatti, Ester ^a   Pucillo, Carlo ^c   Maio, Michele ^a,d  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DNA; FOCAL ADHESION KINASE; HLA ANTIBODY; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; MONOCLONAL ANTIBODY L243; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL AGGREGATION; CELL STRAIN MEL 120; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CELL AGGREGATION; CELL DIVISION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FOCAL ADHESION KINASE 1; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; MOLECULAR WEIGHT; NEOPLASM METASTASIS; PHOSPHORYLATION; PRECIPITIN TESTS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; TYROSINE; UP-REGULATION;

EID: 3042773862     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20015     Document Type: Article

References (32)

1. Ahsmann EJ, Boom SE, Lokhorst HM, Rijksen G, Bloem AC. 1997. Anti-adhesive signals are mediated via major histocompatibility complex class II molecules in normal and neoplastic human B cells: Correlation with B cell differentiation stage. Eur J Immunol 27: 2688-2695.
2. Altomonte M, Pucillo C, Damante G, Maio M. 1993. Cross-linking of HLA class II antigens modulates the release of tumor necrosis factor-α by the EBV-B lymphoblastoid cell line JY. J Immunol 151: 5115-5122.
3. Altomonte M, Simonelli C, Tirelli U, Maio M. 1995. Signaling by HLA class II antigens on B cells. Immunol Today 16:548.
4. Altomonte M, Pucillo C, Maio M. 1999. The overlooked "non classical" functions of Major Histocompatibility Complex (MHC) class II antigens in immune and non immune cells. J Cell Physiol 179:251-256.
5. Altomonte M, Fonsatti E, Visintin A, Maio M. 2003. Targeted therapy of solid malignancies via HLA Class II antigens: A new biotherapeutic approach? Oncogene 22:6564-6569.
6. Bagnato A, Tecce R, Di Castro V, Catt KJ. 1997. Activation of mitogenic signal by endothelin 1 in ovarian carcinoma cells. Cancer Res 57:1306-1311.
7. Bernsen MR, Hakansson L, Gustafsson B, Krysander L, Rettrup B, Ruiter D, Hakansson A. 2003. On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases. Br J Cancer 88:424-431.
8. Cambier JC, Newell MK, Justement LB, McGuire JC, Leach KL, Chen ZZ. 1987. Ia binding ligands and cAMP stimulate nuclear translocation of PKC in B lymphocytes. Nature 327:629-632.
9. Coral S, Pucillo C, Leonardi A, Fonsatti E, Altomonte M, Maio M. 1997. Triggering of HLA-DR antigens differentially modulates tumor necrosis factor alpha release by B cells at distinct stage of maturation. Cell Growth Differ 8:581-588.
10. Dong Z, Crawford HC, Lavrovsky V, Taub D, Watts R, Matrisian LM, Colburn NH. 1997. A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol- 13-acetate-induced invasion in mouse keratinocytes. Mol Carcinog 19:204-212.
11. Germain RN, Castellino F, Han R, Reis Sousa C, Romagnoli P, Sadegh-Nasseri S, Zhong GM. 1996. Processing and presentation of endocytically aquired protein antigens by MHC class II and class I molecules. Immunol Rev 151:5-30.
12. Giancotti FG. 1997. Integrin signaling: Specificity and control of cell survival and cell cycle progression. Curr Opin Cell Biol 9:691-700.
13. Kahana O, Micksche M, Witz IP, Yron I. 2002. The focal adhesion kinase (P125FAK) is constitutively active in human malignant melanoma. Oncogene 21:3969-3977.
14. Koulova L, Clark EA, Shu G, Dupont B. 1991. The CD28 Ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T Cells. J Exp Med 173:759-762.
15. Leonardi A, Altomonte M, Maio M, Tell G, Bearz A, Formisano S, Pucillo C. 1997. Biphasic control of NF-kappa B activation induced by the triggering of HLA-DR antigens expressed on B cells. Cytokine 9:295-299.
16. Maio M, Tessitori G, Pinto A, Temponi M, Colombatti A, Ferrone S. 1989. Differential role of distinct determinants of intercellular adhesion molecule-1 in immunologic phenomena. J Immunol 143: 181-188.
17. Mourad W, Al-Daceak R, Chatila T, Geha RS. 1993. Staphylococcal superantigens as inducers of signal transduction in MHC class II-positive cells. Semin Immunol 5:47-55.
18. Nabavi N, Freeman GJ, Gault A, Godfrey D, Nadler LM, Glimcher LH. 1992. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 360:266-268.
19. Nagy ZA, Huber B, Loaning C, Rauchenberger R, Reiffert S, Thomassen-Wolf E, Zahn S, Leyer S, Schier EM, Zahradnik A, Brunner C, Lobenwein K, Rattel B, Stanglmaier M, Hallek M, Wing M, Anderson S, Dunn M, Kretzschmar T, Tesar M. 2002. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med 8:801-807.
20. Naitoh K, Ichigi Y, Miyake K, Muraguchi A, Kimoto M. 1994. Signal transmission through MHC class II molecules in a human B lymphoid progenitor cell line: Different signaling pathways depending on the maturational stages of B cells. Microbiol Immunol 38: 967-976.
21. Natali PG, Cavaliere R, Bigotti A, Nicotra MR, Russo C, Ng AK, Giacomini P, Ferrone S. 1983. Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol 130:1462-1466.
22. 1 phase of the cell cycle. J Cell Biol 145:1461-1469.
23. Ozanne BW, McGarry L, Spence HJ, Johnston I, Winnie J, Meagher L, Stapleton G. 2000. Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer 36: 1640-1648.
24. Renkvist N, Castelli C, Robbins PF, Parmiani G. 2001. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3-15.
25. Rubinstein E, Le Naour F, Lagaudriere-Gesbert C, Billard M, Conjeaud H, Boucheix C. 1996. CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. Eur J Immunol 26:2657-2665.
26. Shaulian E, Karin M. 2002. AP-1 as a regulator of cell life and death. Nat Cell Biol 4:131-136.
27. Si Z, Hersey P. 1993. Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma. Int J Cancer 54:37-43.
28. Taramelli D, Fossati G, Mazzocchi A, Delia D, Ferrone S, Parmiani G. 1986. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. Cancer Res 46:433-439.
29. Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S. 1989. Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: Comparison with other methods of purification. Hybridoma 8:85-95.
30. van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, Ferrone S. 1998. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 48:1019-1025.
31. Weinberg RA. 1995. The molecular basis of oncogenes and tumor suppressor genes. Ann NY Acad Sci 758:331-338.
32. Yuspa SH. 1998. The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis. J Dermatol Sci 17:1-7.